骨质疏松大鼠骨髓白细胞介素6受体亚单位gp80和gp130基因的表达被引量：1

Expressions of IL-6 receptor subunit gp80 and gp130 genes in bone marrow of osteoporotic rat

导出

摘要以竞争性RT PCR研究骨质疏松模型大鼠骨髓白细胞介素 6受体亚单位gp80和 gp13 0基因的表达。结果表明这些骨质疏松大鼠的 gp80和gp13 0mRNA基因表达增加 ,该变化可能为雌激素丢失所致骨质疏松的形成机制之一。 Gene expressions of interleukin-6 receptor subunit gp130 and gp80 were investigated by competitive RT-PCR in the rat model of osteoporosis. A significant increase in expressions of gp130 and gp80 was found in bone marrow of osteoporotic rat, this change may be a possible mechanism in osteoporosis due to loss of estrogen.

作者罗江张秀珍

机构地区上海同济大学同济医院内分泌科

出处《中华内分泌代谢杂志》 CAS CSCD 北大核心 2003年第6期494-495,共2页 Chinese Journal of Endocrinology and Metabolism

基金国家自然科学基金资助 (30 0 70 357)

关键词骨质疏松大鼠骨髓白细胞介素6受体亚单位 gp80 GP130 基因表达雌激素丢失 Osteoporosis Receptors, interleukin-6 Rats, Sprague-Dawley

分类号 R58 [医药卫生—内分泌]

引文网络
相关文献

参考文献1

1权金星,李茂欣,王宝利,邱明才,郭善一,高林.正常和去卵巢大鼠骨组织白细胞介素6 mRNA表达水平的研究[J].中华内分泌代谢杂志,2001,17(5):320-321. 被引量：1

二级参考文献1

1朱梅，中华妇产科杂志，1999年，34卷，86页

同被引文献14

1丁桂芝,刘忠厚,周勇.中西医结合防治骨质疏松症的基础与临床研究进展[J].中国骨质疏松杂志,1997,3(2):81-84. 被引量：121
2Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med,1990,323:73-79.
3Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest, 1996,97:2692-2696.
4Compston JE. The therapeutic use of bisphosphnates. BMJ, 1994,309:711-715.
5Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopansal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis Int, 1999,9:461-468.
6Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis : the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab,2000, 85:4118-4124.
7Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Dev Comp Immunol, 1997,21:487-499.
8Roodman GD. Role of cytokines in the regulation of bone resorption.Calcif Tissue Int, 1993,53Suppl 1:S94-98.
9Natale VM, Filho WJ, Duarte AJ. Dose the secretion of cytokines in the periphery reflect their role in bone metabolic disease? Mech Ageing Dev, 1997,94 : 17-23.
10Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med, 1998, 128:127-137.